T Cell Modulation

Modulation of the patient’s T cells may help attack cancer cells1

A critical component of the immunological response to cancer cells is dependent on a robust T effector cell response that is specific for tumor associated-antigens. Effective T cell activation, a consequence of both receptor-antigen-MHC binding and engagement of co-stimulatory molecules, is required to drive a vigorous immune response.1

Despite ongoing surveillance by T cells and other components of the immune system, tumors continually evolve and adapt in order to evade immune surveillance and destruction.1 The goal of immunotherapy in cancer is to assist the immune system to overcome the multiple evasive mechanisms engaged by cancer cells, permitting an effective host anti-tumor immune response leading to prolong responses.1 GITR is a key stimulatory protein involved in the priming and activation of effector T cell responses.2 GITR-GITRL interactions may support effective anti-tumor immune responses, both by promoting expansion and activation of effector T cell populations and by suppressing T reg functions, which suppress immune activity.2

  1. Chen DS, et al. Immunity. 2013;39:1-10.
  2. Schaer DA, et al. J Immunother Cancer. 2014;2:7.

GITR: An Investigational Target to Enhance Antitumor Immune Response in Cancer ->